Devices & Diagnostics

Cancer treatment company NeuWave raises $5.5 million

The U.S. Food and Drug Administration in late October granted a 510(k) marketing clearance for NeuWave's Certus 140TM 2.45 GHz Ablation System. The device attacks tumors with microwave energy in a way that cuts treatment times.

By Chris Seper on December 30, 2010 2:47 pm

The Wisconsin medical device company NeuWave Medical has raised more than $5.5 million ahead of its sales efforts for a cancer treatment that recently won federal approval, according to regulatory filings.

The U.S. Food and Drug Administration in late October granted a 510(k) marketing clearance for NeuWave’s Certus 140TM 2.45 GHz Ablation System. The device attacks tumors with microwave energy in a way that cuts treatment times, can more accurately target tissue and utilizes a smaller-diameter needle, according to the company.

NeuWave said in November it would begin selling the Certus device in January. While the company closed on $5.5 million in funding, it could raise up to $8 million, according to its filing with the Securities and Exchange Commission.

Wisconsin’s Venture Investors is among the investors in NeuWave.